COMMUNIQUÉS West-GlobeNewswire

Lexicon Announces Completion of Screening in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

22/10/2024 - 14:00

Top-line Data Now Anticipated in Q1 2025 LX9211 has previously received Fast Track designation from the U.S. Food and Drug Administration (FDA) for DPNP THE WOODLANDS, Texas, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Lexicon [...]

Viemed Healthcare Announces Third Quarter 2024 Earnings Conference Call Details

22/10/2024 - 14:00

LAFAYETTE, La., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “ Company ” or “ Viemed ”) (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, today [...]

Quoin Pharmaceuticals Announces Further International Expansion of Ongoing Clinical Trials for Netherton Syndrome

22/10/2024 - 14:00

Two Additional Clinical Sites to be Opened in the United Kingdom Both Sites are Recognized Centers of Excellence for Netherton Syndrome in the UK. Principal Investigator has Been Appointed and a Clinical Research [...]

ProPhase Labs to Present at the 2024 ThinkEquity Conference

22/10/2024 - 14:00

GARDEN CITY, NY, Oct. 22, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation biotech, genomics, and diagnostics company, today announced that it will be [...]

InnovAge to Announce Fiscal First Quarter 2025 Financial Results and Host Conference Call Tuesday, November 5, 2024

22/10/2024 - 14:00

DENVER, Oct. 22, 2024 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, and predominantly dual-eligible [...]

Scorpius Holdings Announces Partnership with U.S. Biotech Company

22/10/2024 - 14:00

Agreement reinforces Scorpius' position as a respected U.S. biomanufacturing partner for early-stage and clinical development DURHAM, N.C., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX [...]

ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases

22/10/2024 - 13:57

Recent evidence links obesity-driven inflammation to diminished brain health and neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseases The newly published data show that obesity leads to progressive [...]

BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data

22/10/2024 - 13:50

55% of BriaCell patients 1 remained alive one year since enrollment in BriaCell’s Phase 2 study, markedly exceeding the survival rate of current standard of care for similar patients Multiple outperforming patients with [...]

Coave Therapeutics Showcases Breakthrough in Peptide-Based Conjugated AAV Vectors Using ALIGATER™ Platform in a Late-Breaking Abstract at ESGCT 2024

22/10/2024 - 12:00

Coave’s proprietary ALIGATER platform enables specific retargeting of AAV vectors to human receptors via a one-step chemical conjugation of peptide-based ligands at the surface of the capsid, bypassing the need for [...]

Half of Canadians delay seeking medical advice despite health concerns, Maple report reveals

22/10/2024 - 10:00

New report uncovers critical barriers preventing Canadians from accessing proactive care, leading to delayed treatment and added healthcare system strain TORONTO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Today, Maple, Canada’s [...]

Laverock Therapeutics to Present New Data on Programmable, Tunable, Stable and Specific Gene Silencing Platform at ESGCT

22/10/2024 - 10:00

STEVENAGE, United Kingdom, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Laverock Therapeutics, a gene-silencing company with a uniquely powerful technology for the development of programmable advanced therapies to tackle major [...]

EBC 24 – Conference Programme Unveiled

22/10/2024 - 10:00

BERLIN, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Europe’s leading business and discussion forum within the global bioplastics sector, the European Bioplastics Conference (EBC 24), has just released its programme. The [...]

Vivet Therapeutics Presents Three Posters on Cerebrotendinous Xanthomatosis Program and Novel AAV Gene Delivery Platform at European Society of Gene and Cell Therapy Annual Congress 2024

22/10/2024 - 09:30

Vivet Therapeutics Presents Three Posters on Cerebrotendinous Xanthomatosis Program and Novel AAV Gene Delivery Platform at European Society of Gene and Cell Therapy Annual Congress 2024 Paris, France, October 22, 2024 [...]

BioPorto is proud to have Nine of the top-ten best US Children’s hospitals as customers of NGAL

22/10/2024 - 08:04

October 22, 2024 News Release BioPorto is proud to have Nine of the top-ten best US Children’s hospitals as customers of NGAL COPENHAGEN, DENMARK and BOSTON, MA, USA, October 22, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S ( [...]

Ring Therapeutics Presents Preclinical Data on Anellogy™ Platform at the 31st Annual European Society of Gene & Cell Therapy Conference

22/10/2024 - 08:00

- Data further validates the AnelloVector™ platform as the first gene delivery vector system based on the human commensal anellovirus CAMBRIDGE, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Ring Therapeutics , a life [...]

Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress

22/10/2024 - 08:00

NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving [...]

Epicrispr Biotechnologies Presents Data on Powerful Gene Reactivation with GEMS Epigenetic Editors at ESGCT

22/10/2024 - 08:00

– Company’s non-cutting technology, engineered to be even more compact and deliverable, demonstrates synergistic gene reactivation in vitro – SOUTH SAN FRANCISCO, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Epicrispr [...]

Cellectis présentera des données sur des TALE Base Editors ainsi que sur son programme de thérapie génique non-virale lors du 31ème congrès annuel de l’ESGCT

22/10/2024 - 08:00

NEW YORK, 22 oct. 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de génome TALEN® pour développer [...]

Crossject reports strong manufacturing progress with its epilepsy rescue therapy ZEPIZURE® ahead of filing U.S. Emergency Use Authorization

22/10/2024 - 07:30

Product batch announced in July yielded new regulatory stability data. These results will directly support the requested 6-month stability data in the first quarter of 2025 Crossject expects to file for EUA early next [...]